Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
William H. Towns
Observed names:
Towns H William,
W.H. Towns,
William Towns
Observed institutions:
University of Utah,
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University Wexner Medical Center,
Center for Molecular Medicine and Immunology,
The Ohio State University
OpenAlex ID:
A5008015101
Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
2013
·
Jennifer A. Woyach
, Engin Bojnik
, et al.
·
Blood
·
220
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
2014
·
Jason A. Dubovsky
, Ryan Flynn
, et al.
·
Journal of Clinical Investigation
·
204
PDF
A Mouse Model for the Carney Complex Tumor Syndrome Develops Neoplasia in Cyclic AMP–Responsive Tissues
2005
·
Lawrence S. Kirschner
, Donna F. Kusewitt
, et al.
·
Cancer Research
·
175
17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
2010
·
Erin Hertlein
, Amy J. Wagner
, et al.
·
Blood
·
104
Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease
2013
·
Erin Hertlein
, Kyle A. Beckwith
, et al.
·
PLoS ONE
·
65
PDF
Heart-Specific Ablation of Prkar1a Causes Failure of Heart Development and Myxomagenesis
2008
·
Zhirong Yin
, Georgette N. Jones
, et al.
·
Circulation
·
56
PDF
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
2011
·
Lapo Alinari
, Emilia Mahoney
, et al.
·
Blood
·
55
Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol
2012
·
Lapo Alinari
, Courtney J. Prince
, et al.
·
Clinical Cancer Research
·
40
Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice
2012
·
Darlene M. Rozewski
, Sarah E. M. Herman
, et al.
·
The AAPS Journal
·
35
PDF
Tissue-Specific Ablation of Prkar1a Causes Schwannomas by Suppressing Neurofibromatosis Protein Production
2008
·
Georgette N. Jones
, Chhavy Tep
, et al.
·
Neoplasia
·
35
PDF
Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2012
·
Yicheng Mao
, Georgia Triantafillou
, et al.
·
Clinical Cancer Research
·
34
Mutation of Prkar1a Causes Osteoblast Neoplasia Driven by Dysregulation of Protein Kinase A
2007
·
Emilia Pavel
, Kiran Nadella
, et al.
·
Molecular Endocrinology
·
34
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
2014
·
John T. Patton
, Mark E. Lustberg
, et al.
·
Oncotarget
·
30
PDF
FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death
2011
·
Lapo Alinari
, Emilia Mahoney
, et al.
·
Blood
·
4
OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells
2013
·
Ta-Ming Liu
, YongHua Ling
, et al.
·
Blood
·
3
Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
2012
·
Jennifer A. Woyach
, Matthew R Stefanovski
, et al.
·
Blood
·
3
Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,
2011
·
Lapo Alinari
, Ryan B. Edwards
, et al.
·
Blood
·
2
Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production
2008
·
G.N. Jones
, C. Tep
, et al.
·
European Journal of Cancer Supplements
·
1
Supplementary Figure 1 from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
Supplementary Figure Legend from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
PDF
Data from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
Data from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
Supplementary Figure Legend from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
Supplementary Figure 1 from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
2023
·
Yicheng Mao
, Georgia Triantafillou
, et al.
PDF
Abstract 2591: Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation
2014
·
Jason A. Dubovsky
, Ryan Flynn
, et al.
·
Cancer Research
Show more works
View as search
Works count:
27
Citation count:
1,100
H-index:
13
I10-index:
13
Year
Topic
Type
